Abstract
Background The rapid global spread of SARS-COV-2 forced governments to implement drastic interventions. The existence of a large but undetermined number of mild or non-symptomatic but infectious cases seems to be involved in the rapid spread, creating a high level of uncertainty due to the difficulty to measure them, and difficulty for epidemiologic modelling.
Methods We developed a compartmental model with deterministic equations, that accounts for clinical status, mobility, r heterogenous susceptibility and non-pharmaceutical interventions. The model was calibrated using data from different regions and we used it to predict the dynamic in Buenos Aires Metropolitan Area (AMBA).
Results The model adjusted well to different geographical regions. In AMBA the model predicted 21400 deaths at 300 days, with 27% of the population in the region immunized after the first wave, partly due to the high incidence of asymptomatic cases. The mobility restriction is approximately linear, with any restriction bringing a positive effect. The other interventions have a combined effect of 27% reduction in infection rates.
Conclusion Our research underlines the role of asymptomatic cases in the epidemics’ dynamic and introduces the concept of susceptibility heterogeneity as a potential explanation for otherwise unexplained outbreak dynamics. The model also shows the big role of non-pharmaceutical interventions both in slowing down the epidemic dynamics and in reducing the eventual number of deaths. The model results are closely compatible with observed data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted using public data from open sources and did not require a specific IRB approval, in accordance with relevant guidelines
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Santiago Poy-Piñeiro: santiago_poy{at}uca.edu.ar, Pedro Cosatto Ammann: pedrocosatto{at}uca.edu.ar, Hernan Seoane: hseoane{at}uca.edu.ar, Emilio Picasso: epicasso{at}uca.edu.ar
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos